Protein phosphatase 1 and 2A inhibitors activate acyl-CoA:cholesterol acyltransferase and cholesterol ester formation in isolated rat hepatocytes.
Okadaic acid, calyculin A and cantharidin, potent and specific inhibitors of protein phosphatases 1 (PP1) and 2A (PP2A), stimulated both acyl-CoA:cholesterol acyltransferase (ACAT) activity and cholesterol ester formation in suspension cultures of isolated rat hepatocytes. The activation of microsomal ACAT was marked (up to 14-fold the basal values), fast in onset (within 5 min), persistent in duration (up to 45 min) and concentration-dependent. Concentrations of okadaic acid (OA) or calyculin A > or = 100 nM or of cantharidin > or = 1 microM were required to stimulate enzyme activity, which specifically points to a dominant contribution of PP1. No effects were seen with up to 1 microM nor-okadaone, an inactive OA analogue. Rises in [3H]oleate incorporation into cell cholesteryl esters closely paralleled those in ACAT activity, though were somewhat less accentuated. The increases in microsomal ACAT activity seen in OA-, calyculin A- or cantharidin-treated hepatocytes were not linked to changes in bulk microsomal unesterified cholesterol or in the de novo cholesterol synthesis. The findings firmly indicate a role for protein phosphatase activity, probably that of PP1, in controlling the cholesterol esterification rate and ACAT activity in intact rat hepatocytes, which is not secondary to an alteration of the steady-state distribution of cholesterol mass between cell membranes. However, as the OA-induced stimulation of ACAT was not abrogated by addition of purified PP1 or PP2A to microsomes, it is unlikely that the phosphatase inhibitors here used act directly on the phosphorylation degree of the ACAT enzyme.
Hernández
M L
ML
Department of Physiology, University of the Basque Country Medical School, Bilbao, Spain.
Martínez
M J
MJ
López de Heredia
M
M
Ochoa
B
B
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D002193:Cantharidin / Q000494:pharmacology; D002478:Cells, Cultured; D002788:Cholesterol Esters / Q000378:metabolism*; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D008099:Liver / Q000166:cytology / Q000187:drug effects / Q000201:enzymology*; D008148:Lovastatin / Q000494:pharmacology; D008387:Marine Toxins; D008862:Microsomes, Liver / Q000201:enzymology; D019319:Okadaic Acid / Q000494:pharmacology; D019301:Oleic Acid / Q000378:metabolism; D010080:Oxazoles / Q000494:pharmacology; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010766:Phosphorylation; D054645:Protein Phosphatase 1; D051381:Rats; D017207:Rats, Sprague-Dawley; D002785:Sterol O-Acyltransferase / Q000378:metabolism*; D013997:Time Factors
D000924:Anticholesteremic Agents; D002788:Cholesterol Esters; D004791:Enzyme Inhibitors; D008387:Marine Toxins; D010080:Oxazoles; D019319:Okadaic Acid; D019301:Oleic Acid; C059041:calyculin A; D008148:Lovastatin; D002785:Sterol O-Acyltransferase; D010749:Phosphoprotein Phosphatases; D054645:Protein Phosphatase 1; D002193:Cantharidin